Menu
Recruiting NCT06260072

Magnesium and Riboflavin Treatment for Post-Concussion Headache

Phase II Interventional Concussion, Intermediate

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: magnesium and riboflavin supplement.
Who it may be relevant to
Registry conditions: Concussion, Intermediate. Basic parameters: 18 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person.

Interventions

  • Drug magnesium and riboflavin supplement
    Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)

Primary outcome measures

  • Headache Intensity and Duration [Time frame: 14 days]

Eligibility criteria

Inclusion criteria

  • Seen at University of Virginia Student Health and Wellness Center or Emergency Department for Initial Visit for Concussion;
  • Less than 3 days have elapsed since their injury;
  • Able to swallow capsules

Exclusion criteria

  • Concussion complicated by cranial bleed, skull fracture, additional severe injury;
  • Kidney disfunction or failure;
  • Significant gastro-intestinal dysfunction;
  • Varsity Athlete;
  • Two or more previous concussions;
  • Women who are pregnant or breast feeding;
  • Taking tetracycline, fluoroquinolone, iron digoxin, chlorpromazine or penicillamine

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • University of Virginia Student Health and Wellness Center — Charlottesville

Identifiers

NCT: NCT06260072 · IRB-HSR 21920

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗